Review
Version 1
This version is not peer-reviewed
Antibody Drug Conjugates in the Treatment of Urothelial Cancer: The Dawn of a New Era
Version 1
: Received: 31 July 2024 / Approved: 1 August 2024 / Online: 2 August 2024 (03:52:03 CEST)
How to cite: Pistamaltzian, N.; Zylis, D. Antibody Drug Conjugates in the Treatment of Urothelial Cancer: The Dawn of a New Era. Preprints 2024, 2024080057. https://doi.org/10.20944/preprints202408.0057.v1 Pistamaltzian, N.; Zylis, D. Antibody Drug Conjugates in the Treatment of Urothelial Cancer: The Dawn of a New Era. Preprints 2024, 2024080057. https://doi.org/10.20944/preprints202408.0057.v1
Abstract
This review critically evaluates the role of Antibody-drug conjugates (ADCs) in the treatment of urothelial cancer, exploring their therapeutic potential and addressing the scientific and clinical challenges encountered in the development of these agents. It also discusses the recent approvals and clinical trials that are shaping the future of ADC therapy in this field. Through a detailed examination of the mechanism of action of ADCs, including the bystander effect, this paper aims to highlight both the successes and the limitations of these drugs in clinical settings. The main objective of this work is to provide a thorough overview of the current state of ADCs in urothelial cancer treatment, elucidating how these drugs can offer improved outcomes for patients. By discussing the broader implications of ADC technology and its integration into existing treatment paradigms, this review outlines the next steps in research and application necessary to overcome the existing challenges and harness the full potential of ADCs in cancer therapy.
Keywords
antibody-drug conjugates; urothelial cancer; enfortumab vedotin; bystander effect
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
